Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program

  • Gilead Sciences Inc GILD and Jounce Therapeutics Inc JNCE amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. 
  • GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment.
  • It is currently in Phase 1 development for solid tumors.  
  • Jounce will receive proceeds of $67 million for this transaction, and Gilead will be solely responsible for all further research, development, and commercialization of GS-1811 globally
  • Gilead expects the transaction with Jounce to reduce its GAAP and non-GAAP 2022 EPS by approximately $0.04. 
  • Jounce will no longer be entitled to receive the remaining contingent payments of up to $645 million in milestones and high single-digit to mid-teens royalties based upon worldwide sales under the original license agreement. 
  • Price Action: JNCE shares are up 68.2% at $1.24 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapM&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!